Dr Sheldon Holder Wins CureAccelerator Grant
[Written by Stephen Wright]
Dr Sheldon Holder has been selected as one of two winners of the prestigious CureAccelerator programme and will receive a $70,000 grant to support his clinical trial.
The Bermudian, a physician-scientist in the Cancer Centre at Brown University in Providence, Rhode Island, was among four finalists in CureAccelerator Live! – a virtual event where researchers present their clinical trials.
Dr Holder delivered a presentation to community members representing industry, research, medicine, philanthropy and patient groups on repurposing the prostrate drug degarelix to treat bladder cancer.
“Thank you for making this opportunity possible,” Dr Holder tweeted today. “I am honoured to receive this CureAcceleratorLive! for DEI [Diversity, Equity and Inclusion] funding. I look forward to partnering to improve therapy for bladder cancer patients.”
Also receiving a $70,000 clinical grant was Dr Edilberto Amorim, MD, representing the University of California, San Francisco, testing the epilepsy drug perampanel to prevent seizures after cardiac arrest.
Dr Holder is an assistant professor in the Department of Pathology and Laboratory Medicine at Brown University and an attending physician in the Division of Hematology/Oncology at the Lifespan Cancer Institute.
He obtained his Bachelor of Science degree from Oakwood University in Huntsville, Alabama, and his MD/PhD from Loma Linda University in California.
Dr Holder completed Internal Medicine Residency training at the Penn State Milton S Hershey Medical Centre and Hematology/Oncology Fellowship training at the Vanderbilt-Ingram Comprehensive Cancer Centre.
